MK-0812

• Description:

  MK-0812 is a potent and selective CCR2 antagonist with low nM affinity for CCR2.

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319

• Target:

  CCR

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein; Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology; Endocrinology

• Assay Protocol:

  https://www.medchemexpress.com/mk-0812.html

• Purity:

  99.89

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C ([C@]1 (C (C) C) C[C@H] (N[C@H]2CCOC[C@H]2OC) CC1) N3CCC (N=CC (C (F) (F) F) =C4) =C4C3

• Molecular Formula:

  C24H34F3N3O3

• Molecular Weight:

  469.54

• Precautions:

  H302, H315, H319

• References & Citations:

  [1]Wisniewski T, et al. Assessment of chemokine receptor function on monocytes in whole blood: In vitro and ex vivo evaluations of a CCR2 antagonist.J Immunol Methods. 2010 Jan 31;352 (1-2) :101-10.|[2]Min SH, et al. Pharmacological targeting reveals distinct roles for CXCR2/CXCR1 and CCR2 in a mouse model of arthritis.Biochem Biophys Res Commun. 2010 Jan 1;391 (1) :1080-6.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 2

• Isoform:

  CCR2

• CAS Number:

  624733-88-6